The Discovery That Changed Medicine Forever

In 1951, a 31-year-old African American woman named Henrietta Lacks visited Johns Hopkins Hospital in Baltimore, Maryland, complaining of abdominal pain and bleeding. Doctors diagnosed her with an aggressive form of cervical cancer. During treatment, a surgeon removed tissue samples from her tumor—without her knowledge or consent—and sent them to a laboratory run by Dr. George Gey. Gey had been trying for years to grow human cells in culture, but all his attempts died after a few divisions. Henrietta’s cells were different. They not only survived but doubled every 20 to 24 hours, forming what appeared to be an immortal cell line.

Gey named the line “HeLa,” using the first two letters of Henrietta Lacks’ first and last names. HeLa cells became the first human cells ever to be successfully cloned and continuously cultured outside the human body. This breakthrough opened a new era in biomedical research, providing scientists with an unlimited supply of identical human cells for experiments that could not be performed on living people.

Henrietta Lacks died on October 4, 1951, but her cells lived on. Today, the total mass of HeLa cells that have been grown in labs around the world is estimated to exceed 50 million metric tons—enough to fill a hundred Empire State Buildings. What began as a single tissue sample has become the most widely distributed human cell line in history, used in tens of thousands of experiments across every continent.

Why HeLa Cells Became a Scientific Workhorse

The unique properties of HeLa cells made them ideal for research. They grow robustly, can be frozen and thawed without dying, and can be shipped to laboratories worldwide. Unlike earlier primary cultures that required fresh tissue each time, HeLa cells allowed researchers to repeat experiments under identical conditions and share results across institutions.

The First Human Cell Line

Before HeLa, scientists worked with animal cells or direct human tissue samples. These were difficult to obtain and maintain. HeLa provided a standardized, renewable resource that enabled large-scale research. Their ability to divide indefinitely was due to an abnormally active telomerase enzyme, which rebuilds the protective caps at the ends of chromosomes each time a cell divides, preventing the usual aging process. This mechanism of cellular immortality made HeLa cells uniquely suited for long-term experiments and drug screenings.

The robustness of HeLa cells also allowed them to adapt quickly to culture conditions. While other cell lines required precise nutrient formulations and careful handling, HeLa could thrive in a wider range of laboratory environments. This hardiness meant that even less experienced technicians could successfully maintain the line, accelerating its adoption across academic medical centers, government labs, and pharmaceutical companies.

HeLa cells also exhibit a remarkably stable karyotype—the number and appearance of their chromosomes—despite having undergone thousands of divisions. Although they are cancer cells with an abnormal number of chromosomes, that chromosomal composition has remained largely consistent over decades. This stability gave researchers confidence that results obtained in 1960 could be meaningfully compared with experiments conducted in 1990, a reproducibility that was unheard of with previous tissue models.

Contamination and Its Consequences

HeLa cells are so hardy that they sometimes contaminated other cell cultures in labs. In the 1960s and 1970s, researchers discovered that many “new” cell lines were actually HeLa cells that had accidentally taken over. This cross-contamination compromised decades of research. Today, strict cell line authentication standards require using genetic fingerprinting to verify cell identity, an approach that grew directly from the HeLa contamination problem. The lesson has driven the development of standardized cell repositories and mandatory authentication protocols for all published studies involving cell lines.

One prominent example was the “HEp-2” line, originally thought to be derived from a laryngeal cancer, which turned out to be HeLa. Similarly, the “KB” line, believed to come from an oral tumor, was also HeLa. These errors misled researchers for years until Walter Nelson-Rees and other cell biologists systematically documented the contamination patterns. The problem was so widespread that some estimates suggest as many as 20% of all cell lines in use during the 1970s were actually HeLa. The scientific community was slow to respond, but eventually, the pressure to adopt authentication standards became overwhelming. Now, major journals require authors to provide genetic validation of all cell lines used in experiments before publication.

Major Medical Breakthroughs Enabled by HeLa Cells

HeLa cells have been instrumental in countless advances. Below are some of the most significant contributions.

Polio Vaccine Development

In the early 1950s, Jonas Salk needed a way to test his polio vaccine safely and efficiently. HeLa cells provided a scalable system to grow the poliovirus in large quantities and to measure the vaccine’s effectiveness. Using HeLa cells, researchers were able to confirm that the killed-virus vaccine induced protective antibodies without causing disease. This work led to the mass production and distribution of the polio vaccine, which has nearly eradicated the disease worldwide. Learn more about the role of HeLa cells in polio research.

The polio vaccine effort was the first large-scale test of HeLa cells in a clinical context. Millions of HeLa cells were grown in roller bottles, harvested, and infected with poliovirus to produce the viral antigens needed for the vaccine trials. Without a reliable human cell line, the safety and efficacy testing would have required the use of live monkeys, which was both expensive and ethically fraught. HeLa cells allowed Salk to move from laboratory experiments to field trials in an astonishingly short period—just a few years.

Cancer Research and Chemotherapy

HeLa cells allowed scientists to examine how cancer cells divide, respond to drugs, and develop resistance. The cell line was used to test the first chemotherapy drugs and understand how radiation affects malignant cells. Researchers discovered that HeLa cells express high levels of the MYC oncogene and have a mutated p53 tumor suppressor gene—both common features in many human cancers. This made HeLa a model for studying tumor biology and for screening potential anticancer compounds. Today, HeLa cells are still used in cancer drug development and in studies of cell cycle regulation, apoptosis, and metastasis.

HeLa cells were also essential in understanding how chemotherapeutic agents kill dividing cells. In the 1960s and 1970s, researchers at the National Cancer Institute used HeLa to screen hundreds of compounds, identifying the ones that disrupted DNA replication or mitotic spindle formation. Many drugs that emerged from those screens, such as cisplatin and paclitaxel, remain cornerstones of cancer treatment today. The cell line continues to serve as a first-pass test for new anticancer agents because its growth characteristics and drug sensitivities are so well characterized.

Virology and Infectious Disease

HeLa cells have been used to study the life cycle of many viruses, including HIV, herpes simplex, measles, and Ebola. They were crucial in developing the human papillomavirus (HPV) vaccine because HeLa cells contain multiple copies of HPV DNA, allowing scientists to understand how the virus causes cervical cancer. During the COVID-19 pandemic, HeLa cells were used to study SARS-CoV-2 entry mechanisms and to test antiviral drugs such as remdesivir. Their adaptability made them a first-line tool for rapid viral research.

HeLa cells express the ACE2 receptor and the TMPRSS2 protease that SARS-CoV-2 uses to enter human cells. This made them suitable for studying viral entry and screening entry inhibitors. In the early months of the pandemic, when every day counted, HeLa cells provided a reliable platform that did not require specialized biosafety infrastructure beyond standard containment. Researchers could quickly transpose findings from HeLa experiments into more specialized models, accelerating the timeline for vaccine and therapeutic development.

Genetics and Chromosome Mapping

HeLa cells helped establish the number of human chromosomes as 46, correcting the earlier belief that it was 48. They were used in early gene mapping efforts and in studies of gene expression regulation. The HeLa genome was sequenced in 2013 and published without the consent of Henrietta Lacks’ family, sparking renewed ethical debates (discussed below). The cells also provided the first evidence that humans have a diploid chromosome number, a foundational fact for modern genetics.

In addition to establishing the correct chromosome count, HeLa cells have been instrumental in mapping the location of individual genes. In the 1970s, somatic cell hybridization techniques using HeLa allowed researchers to assign genes to specific chromosomes by fusing HeLa cells with mouse cells and tracking which human chromosomes were retained. This approach led to the creation of the first human gene maps. Decades later, the sequencing of the HeLa genome revealed numerous structural variants and rearrangements that reflect the aggressive nature of the original tumor, providing insights into how cervical cancer evolves at the genomic level.

Space Research

HeLa cells have even traveled into space. In the 1960s, they were sent on NASA satellites to study the effects of zero gravity on human cells. More recently, HeLa cells have been used on the International Space Station to investigate how microgravity and cosmic radiation influence cellular aging and cancer progression. These experiments have implications for long-duration spaceflight and astronaut health.

Early space experiments showed that HeLa cells in microgravity divided more slowly and formed three-dimensional aggregates that mimicked tissue-like structures. These findings raised fundamental questions about how the absence of gravity alters cell signaling and gene expression. Modern experiments build on that work by using HeLa cells to test the effectiveness of radiation shielding materials and to study DNA repair mechanisms under the unique stress of space travel. The results are shaping the design of future missions to the Moon and Mars.

The Ethical Failures That Shaped Modern Bioethics

The story of HeLa cells is not just a scientific triumph; it is also a cautionary tale about exploitation and lack of consent in medical research. Henrietta Lacks was never told that her cells would be taken or used for research. She and her family received no compensation, and for decades, the Lacks family was kept in the dark about the worldwide use of Henrietta’s cells.

In 1951, there were no laws requiring informed consent for tissue donation. Doctors routinely collected samples from patients, especially minority patients, without permission. Henrietta Lacks’ case became a symbol of the systemic racism and disregard for patient autonomy that characterized much of 20th-century medicine. Her family learned about the HeLa cell line only in the 1970s, more than two decades after her death, when a journalist called them for an interview. This lack of transparency extended for decades, with the family receiving no updates or recognition as the cells generated billions of dollars in commercial revenue.

The context of the 1950s is important: Johns Hopkins Hospital served a predominantly Black and poor population in Baltimore, and many patients received free care in exchange for allowing medical students to observe their cases. Consent was rarely documented, and the concept of a tissue “donation” did not exist in the legal sense. Henrietta Lacks was one of thousands of patients whose tissues were collected without their knowledge. What makes her case exceptional is that her cells turned out to be uniquely valuable. That value amplified the injustice, making the absence of consent impossible to ignore.

In 2013, scientists published the full genome sequence of a HeLa cell line without consulting the Lacks family. The data could reveal genetic information not only about Henrietta but also about her living descendants. After public outcry, the National Institutes of Health (NIH) brokered an agreement with the Lacks family to control access to the genome data, with two family members joining an advisory board. This marked a significant step toward recognizing the rights of individuals whose genetic material is used in research. Read more about the NIH agreement with the Lacks family.

The 2013 genome publication was a turning point in how the scientific community thinks about genetic privacy. Unlike the original tissue samples taken in 1951, the genomic data could be used to infer traits, disease risks, and family relationships of living individuals. The Lacks family, who had already endured decades of exclusion, found out about the publication from reporters. The NIH agreement, while imperfect, established a precedent for engaging families and communities in governance of genomic data. It also highlighted the need for clear policies about re-consenting donors whose samples are used in new ways that were not anticipated at the time of collection.

Compensation and Ownership

Despite the billions of dollars in commercial activity generated by HeLa cells, the Lacks family has never received direct financial compensation. HeLa cells are sold by biological supply companies and are used in patented products. The question of whether individuals should share in the profits from research on their donated tissues remains unresolved. The HeLa story has fueled ongoing debates about property rights in the human body and the ethics of biobanking. Some legal experts argue that the Lacks family should be entitled to a portion of the revenue, while others worry that profit-sharing could hinder medical advances.

Several court cases have touched on these questions. In Moore v. Regents of the University of California (1990), the California Supreme Court ruled that patients do not retain property rights in cells removed from their bodies, but they do have the right to be informed about the commercial potential of their tissues. That ruling set a precedent that has been followed in most U.S. jurisdictions, but it has been criticized for failing to address the fundamental inequity that HeLa represents. The Lacks family has not pursued litigation, preferring to work through policy and advocacy channels. The Henrietta Lacks Foundation, established by Rebecca Skloot, provides direct support to descendants and other families affected by similar injustices.

Changes in Law and Policy

The injustices suffered by Henrietta Lacks and her family helped drive the development of modern ethical standards. Key reforms include:

  • The Common Rule (1981): Requires Institutional Review Boards to review research involving human subjects and mandates informed consent.
  • The Health Insurance Portability and Accountability Act (HIPAA, 1996): Protects patient medical records and privacy.
  • The NIH HeLa Genome Data Use Agreement (2013): Established a framework for accessing genomic data from HeLa cells with family oversight.
  • Updated consent requirements for biospecimens (2018 revision of the Common Rule): Adds protections for identifiable biospecimens and requires broad consent for future research use.

These policies have transformed how research institutions handle human tissues, but gaps remain. For example, many samples collected before the new rules are still in use without explicit consent from donors. Additionally, the rise of direct-to-consumer genetic testing and large-scale biobanks has introduced new privacy challenges. The HeLa case remains a reference point for these debates, reminding policymakers that ethical frameworks must evolve as technology advances.

The Lasting Legacy of Henrietta Lacks

Henrietta Lacks’ contributions are now widely recognized, and her story has been told in books, documentaries, and a film starring Oprah Winfrey. The Henrietta Lacks Foundation, established by Rebecca Skloot (author of The Immortal Life of Henrietta Lacks), provides scholarships and medical assistance to Henrietta’s descendants and other descendants of medical research subjects who were not given proper consent.

In 2021, the World Health Organization awarded a special posthumous award to Henrietta Lacks for her contribution to science. Johns Hopkins Medicine has publicly apologized for the lack of consent and has committed to continuing community engagement and education. The Lacks family has taken on a role as advocates for patient rights and genetic privacy.

Several statues and memorials have been erected in Henrietta Lacks’ honor, including a bronze bust at the Royal Institution in London and a historical marker at her childhood home in Roanoke, Virginia. These physical tributes ensure that her name is remembered not just as a scientific footnote but as a person whose life and death carry profound moral significance.

Scientific Impact That Continues Today

HeLa cells are still one of the most widely used cell lines in biomedical research. Over 110,000 scientific papers have been published using HeLa cells. They have been used to develop vaccines for HPV and COVID-19, to study the effects of toxins, to explore cellular senescence, and to model rare diseases. The cell line remains a foundational tool in fields ranging from cancer biology to neurobiology.

Moreover, the ethical lessons from Henrietta Lacks have influenced the development of biobanking practices, genomic data sharing policies, and community engagement initiatives in research. Researchers now recognize that informed consent is an ongoing process, not a one-time signature, and that individuals and their families have a stake in how their biological materials are used.

HeLa cells have also become a standard teaching tool in biology and medical education. Students in cell biology courses around the world learn to culture and handle HeLa cells as part of their training. This ubiquity means that every new generation of scientists encounters Henrietta Lacks’ story, often for the first time, in the context of learning laboratory techniques. That exposure creates an opportunity to discuss both the science and the ethics together, shaping how future researchers think about their responsibilities.

Honoring Her Name

For many years, her real name was unknown to the public; she was referred to only as “HeLa.” Today, her full name is acknowledged in textbooks, museums, and scientific honors. Several awards have been established in her name, including the National Institutes of Health Henrietta Lacks Award for health equity and ethical research. Learn about the CDC’s Henrietta Lacks Research Ethics Award.

In 2020, the University of Bristol announced the establishment of the Henrietta Lacks PhD studentship program, supporting scholars from underrepresented backgrounds in biomedical research. That same year, a public school in Maryland was renamed Henrietta Lacks Elementary School—a small but meaningful act that ensures her name is spoken by students every day. These honors reflect a broader reckoning with the history of medical exploitation and a commitment to centering the voices of those who were previously silenced.

Looking Forward: Lessons for the Future of Biomedical Research

The story of Henrietta Lacks is a powerful reminder that scientific progress must go hand in hand with ethical responsibility. As research moves into an era of personalized medicine, gene editing, and artificial intelligence, the principles of consent, fairness, and transparency are more important than ever.

Today’s researchers are required to obtain informed consent before collecting tissue samples, to de-identify data when possible, and to engage communities in research design and governance. The HeLa case also underscores the need for diversity in research: Henrietta Lacks’ cells were unique partly because of her African American heritage, yet minority populations have historically been underrepresented and exploited in research. Addressing these disparities is essential for equitable health outcomes.

New technologies like organoids and induced pluripotent stem cells are creating even more powerful models of human biology, but they also raise fresh ethical questions about ownership, privacy, and consent. The HeLa case provides a template for thinking through these issues: it teaches that the people whose tissues make research possible deserve recognition, respect, and a voice in how their contributions are used.

Finally, the HeLa story highlights the immense and often hidden contributions of individuals who donate their tissues, cells, and data to science. These donors enable breakthroughs that benefit all humanity. Recognizing that contribution—through acknowledgment, privacy protection, and, where appropriate, benefit-sharing—is a fundamental ethical duty.

Henrietta Lacks’ cells transformed medical research, saved countless lives, and forced a reckoning with the moral dimensions of science. Her name will always be linked with both the promise and the peril of using the human body as a resource for discovery. Her legacy challenges us to pursue knowledge with humility, respect, and justice.

As research continues to accelerate, the story of Henrietta Lacks stands as a permanent reference point—a reminder that every cell in every dish has a human story behind it. Scientists, ethicists, and policymakers who take that story to heart will be better equipped to build a future where medical progress and human dignity advance together.

“Henrietta Lacks’ cells changed the world, but her story changed how we think about ethics in science.” – Rebecca Skloot, The Immortal Life of Henrietta Lacks